Skip to main content
. Author manuscript; available in PMC: 2013 Nov 27.
Published in final edited form as: Cancer Res. 2012 May 14;72(14):10.1158/0008-5472.CAN-11-3966. doi: 10.1158/0008-5472.CAN-11-3966

Figure 5. The Ral Transcriptional Signature score is sensitive to androgen status in prostate cancer.

Figure 5

A. Using published expression profiling data for LNCAP cells treated with control or charcoal-stripped (steroid hormone free) medium over a time course of 12 months (43), we observed significant and durable induction of the Ral signature over time in androgen deprived (charcoal stripped serum (CSS) red) as compared to control full serum treated cells (full serum, blue), Mann-Whitney test. B. Quadruplicate KuCAP-2 (44) xenografts were analyzed at androgen-dependent baseline (AD), at castration induced growth nadir (Tx), and during androgen independent (AI) regrowth. A significantly higher Ral signature score was seen in treated and androgen independent tumors (Mann-Whitney test of all treated versus baseline replicates, plot shows median plus 95% CI). C. Consistent with the in vitro and in vivo results in A and B, we observed significantly higher Ral signature scores in a published cohort (45) of androgen independent tumors (N=10) as compared to androgen dependent (N=10) cases (Mann Whitney test, signature scores plotted, and medians indicated per group, black lines). D. We also observed a similar higher Ral signature score in androgen independent cases in a second cohort (46) of androgen independent (N=8) as compared to androgen dependent cases (N=18). E. We observed similar higher Ral signature score in androgen independent metastatic tissues of a third cohort (47) of androgen independent (N=29) as compared to androgen naïve primary cases (N=22).